Compass Pathways: A Higher-Risk But Potentially Higher-Reward Company In The Biotech Arena
December 16, 2023 at 10:40 AM EST
If you can afford it – and if it would not be too big a position in your portfolio – putting $2,000 into a couple of speculative biotechs might be a good idea here. One I like is Compass Pathways.